SCHEMBL9456879

SCHEMBL9456879

CCCCCCCCCC(=O)CCCCCCC[C@@H](CC)OC1CCCCO1

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 2/20 0.39
KMT2A Q03164 2/20 0.36
MAPT P10636 1/20 0.36
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25612545 0.90 ALDH1A1 (0.36) NAAAKMT2AMEN1
SCHEMBL3707695 0.86 FFAR4 (0.46) NAAAKMT2AMEN1
SCHEMBL3700286 0.84 NAAA (0.44) NAAA
SCHEMBL10419766 0.83 FNTA (0.35) NAAAKMT2AMEN1
SCHEMBL10419767 0.83 FNTA (0.35) NAAAKMT2AMEN1
SCHEMBL10419765 0.83 FNTA (0.35) NAAAKMT2AMEN1
SCHEMBL9457368 0.82 GPR84 (0.41) KMT2AMAPTMEN1
SCHEMBL9457193 0.82 GPR84 (0.41) KMT2AMAPTMEN1
SCHEMBL10928665 0.82
SCHEMBL10928661 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5246960-A Used to treat obesity, hyperlipaemia, atherosclerosis and arteriosclerosis HOFFMANN-LA ROCHE INC. (US) 1993-09-21 US disclosed
US-5175186-A Inhibits pancreas lepase and useful agent in treatment of obesity, hyperlipemia, atherosclerosis and arteriosclerosis HOFFMANN-LA ROCHE INC. (US) 1992-12-29 US disclosed
EP-0185359-B1 OXETANONE F. HOFFMANN-LA ROCHE AG (CH) 1991-12-04 EP disclosed
US-4931463-A PANCREAS LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 1990-06-05 US disclosed
EP-0185359-A2 Oxetanone F. HOFFMANN-LA ROCHE AG (CH) 1986-06-25 EP disclosed